Related Experiment Video
Updated: Sep 16, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Nanomedicine initiates ferroptosis for enhanced lung cancer therapy
Yitianhe Xu1, Kaiying Zhang1, Zhanzheng Ye1
1Wenzhou Municipal Key Laboratory of Pediatric Pharmacy, Department of Pharmacy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Abstract:
Lung cancer is the second most common cancer worldwide, with persistently high morbidity and mortality rates. Despite years of research in the field, a complete cure for this disease remains elusive. Current clinical treatment options primarily include chemotherapy, surgery, and targeted drugs. However, these treatments are often limited by the highly metastatic nature of lung tumors and the development of drug resistance, resulting in suboptimal therapeutic outcomes. Ferroptosis is an iron-dependent cell death mechanism driven by lipid peroxidation, offers promising potential to overcome drug resistance in lung cancer. Recent advances in nanotechnology have enabled targeted delivery and precise regulation of ferroptosis pathways, addressing the limitations of conventional therapies. This review systematically summarizes current strategies utilizing nanomedicine to induce ferroptosis in lung cancer, with a focus on key molecular targets, such as GPX4, System Xc-, and FSP1, as well as innovative delivery platforms including metal nanoparticles, nanozymes, and responsive liposomes. Unique challenges in pulmonary drug delivery, such as mucociliary clearance and oxidative microenvironments are also discussed, along with lung cancer-specific solutions like inhalable systems and tumor microenvironment remodeling. Furthermore, we compare ferroptosis nanotherapies across different cancers to highlight the distinctive innovations in lung cancer. This article provides a comprehensive overview of recent progress and proposes optimized strategies to enhance therapeutic efficacy, offering insights into the translational potential of ferroptosis-based nanomedicine in lung cancer treatment.
Insights
Nanomedicine offers a novel approach to treating lung cancer by inducing ferroptosis, an iron-dependent cell death. This strategy targets key molecules and utilizes advanced delivery systems to overcome treatment resistance and improve patient outcomes.
Area of Science:
- Oncology
- Nanomedicine
- Biochemistry
Background:
- Lung cancer remains a leading cause of cancer mortality globally, with current treatments facing limitations due to metastasis and drug resistance.
- Ferroptosis, a form of regulated cell death driven by lipid peroxidation, presents a promising avenue for overcoming therapeutic resistance in lung cancer.
- Conventional therapies often fall short, necessitating innovative treatment strategies for improved efficacy.
Purpose of the Study:
- To systematically review current nanomedicine strategies for inducing ferroptosis in lung cancer.
- To highlight key molecular targets (GPX4, System Xc-, FSP1) and delivery platforms (nanoparticles, nanozymes, liposomes) in ferroptosis induction.
- To discuss challenges and solutions specific to pulmonary drug delivery and lung cancer treatment.
Main Methods:
- Literature review of nanomedicine applications in ferroptosis induction for lung cancer.
- Analysis of molecular targets and nanocarrier systems used in ferroptosis-based therapies.
- Examination of pulmonary drug delivery challenges and lung cancer-specific adaptations.
Main Results:
- Nanomedicine enables targeted delivery and precise regulation of ferroptosis pathways, addressing limitations of conventional lung cancer therapies.
- Various nanoplatforms, including metal nanoparticles and nanozymes, are being explored for efficient ferroptosis induction.
- Strategies for overcoming pulmonary drug delivery barriers and remodeling the tumor microenvironment are crucial for therapeutic success.
Conclusions:
- Ferroptosis-based nanomedicine holds significant potential for overcoming drug resistance and improving lung cancer treatment outcomes.
- Targeted delivery systems and innovative approaches to pulmonary drug delivery are key to enhancing therapeutic efficacy.
- Further research and optimized strategies are needed to translate ferroptosis nanotherapies into clinical practice for lung cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...